TARS News and Press, Tarsus Pharmaceuticals Inc. From 02/03/22

Dr. Trevejo brings over 20 years of clinical development experience to Tarsus as it advances development of TP-03, the first potential treatment for Demodex blepharitis, and its pipeline programs IRVINE, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:...

Revolutionizing Treatment for Demodex Blepharitis Patients event to feature Eric Donnenfeld, M.D.; Paul Karpecki, O.D.; and Elizabeth Yeu, M.D. Webcast scheduled for Tuesday, February 8, 2022 at 9 a.m. Pacific Time IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tarsus P...

Tarsus Pharmaceuticals (NASDAQ:TARS) completed enrollment in a second phase 3 trial, dubbed Saturn-2, of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with Demodex blepharitis; and executed a $175M credit facility with Hercules Capital and Silicon Valley Bank. The study has e...

Topline data expected in April 2022 from Saturn-2, the second Phase 3 pivotal trial of TP-03 and NDA submission remains on track for this year Credit facility with Hercules Capital and Silicon Valley Bank provides availability of non-dilutive capital IRVINE, Calif., Feb. 0...

Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation IRVINE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven s...

IRVINE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participa...

Oppenheimer has initiated Tarsus Pharmaceuticals (TARS +1.6%) with a buy rating and a $55 price target (~118% upside). Analyst Francois Brisebois is optimistic on TP-03 (lotilaner ophthalmic solution), the company's candidate in phase 3 for the eye inflammation condition demodex blepharitis. ...

IRVINE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D...

Tarsus Pharmaceuticals (NASDAQ:TARS): Q3 GAAP EPS of -$0.76 misses by $0.42. Revenue of $1.24M misses by $4.09M. Press Release Cash and equivalents of $184M as of September 30, 2021, for expected runway into the second half of 2023. For further details see: Tarsus Pharmaceuticals E...

On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis; topline data expected in the first quarter of 2022 Data from two pioneering studies on prevalence and impact of Dem...